Immunoassay Blood Test For Amyloid Pathology Assessment
SET is the FDA product code for Immunoassay Blood Test For Amyloid Pathology Assessment, a class II device type, regulated under 21 CFR 866.5840. FDA's definition for this code reads: "An Immunoassay blood test for amyloid pathology assessment is an in vitro diagnostic test used to identify patients with amyloid pathology associated with Alzheimer’s Disease who have signs and symptoms of cognitive decline. The results of the test are to be interpreted in conjunction with other patient clinical...". As of , FDA records hold 4 510(k) clearances under this code, the most recent dated , and 7 recalls.
Classification record
- Product code
- SET
- Device name
- Immunoassay Blood Test For Amyloid Pathology Assessment
- FDA definition
- An Immunoassay blood test for amyloid pathology assessment is an in vitro diagnostic test used to identify patients with amyloid pathology associated with Alzheimer’s Disease who have signs and symptoms of cognitive decline. The results of the test are to be interpreted in conjunction with other patient clinical information.
- Regulation
- 21 CFR 866.5840
- Device class
- Class II
- Review panel
- Immunology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 4
- Ingested recalls
- 7
Clearances, product code SET
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2025 | 2 |
| 2026 | 2 |
Applicants with the most clearances
Product code SET| Applicant | Clearances |
|---|---|
| C2N Diagnostics, LLC | 1 |
| Fujirebio Diagnostics, Inc. | 1 |
| Roche Diagnostics | 1 |
| Roche Diagnostics GmbH | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
